Gujarat Themis Biosyn Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
GUJTHEM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Gujarat Themis Biosyn Limited reported audited financial results for Q4 and year ended March 31, 2026. For FY2026, total income increased to Rs. 16,825.09 lakhs from Rs. 15,323.23 lakhs in FY2025, representing approximately 9.8% revenue growth. However, net profit after tax declined to Rs. 4,668.15 lakhs from Rs. 4,877.17 lakhs, a decrease of about 4.3% year-on-year. EPS for the year stood at Rs. 4.28 compared to Rs. 4.48 in the previous year. The Board recommended a final dividend of Rs. 0.67 per equity share (67% on face value). Additionally, the company proposed a preferential issue of equity shares to non-promoters and re-appointed M/s. Raja Dutta & Co. as Cost Auditor for FY2026-27. Capital work-in-progress increased significantly, indicating major expansion underway, funded partly through increased borrowings.
The company achieved revenue growth but saw a decline in profitability, which may concern investors focused on bottom-line performance. The significant capex and increased borrowings suggest heavy investment in expansion. The clean audit opinion and dividend recommendation provide some stability signals.